Developer docs
API playgroundTry for free, no card

Search company profiles

Ligand Pharmaceuticals

Full company profile

uuid0000mio

Namestring
Ligand Pharmaceuticals
Legal namestring
Ligand Pharmaceuticals Incorporated
Websiteurl
ligand.com
Company typeenum
Public
Founded yearint
1987
Descriptiontext

Ligand Pharmaceuticals is a publicly traded biopharmaceutical royalty aggregator (NASDAQ: LGND) founded in 1987 and headquartered in Jupiter, Florida. The company provides strategic capital to biopharmaceutical companies to finance and advance late-stage clinical development programs, and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with more than 200 commercial, clinical, and preclinical-stage assets following the July 2026 acquisition of XOMA Royalty. Ligand generates revenue primarily through royalties on commercial products developed by partner companies, including key partnered assets such as FILSPARI (9% royalty from Travere for IgA nephropathy and FSGS), OHTUVAYRE (3% from Merck for COPD), VABYSMO (0.50% from Roche), and KYPROLIS (1.5-3% from Amgen).

Ligand operates two proprietary technology platforms. Captisol® is a chemically modified cyclodextrin designed to optimize solubility and stability of drugs, used by partners including Amgen, Merck, Pfizer, Takeda, and Gilead (the latter for Remdesivir for COVID-19). Captisol is incorporated in approximately 17 approved therapies and generated approximately $40 million in royalties in 2025, up 30% year-over-year. NITRICIL™ is a proprietary nitric oxide-based technology platform available for out-license with broad applicability in drug development. The company also conducts supplementary investment activities including royalty financing, project finance, and platform technology acquisitions.

In 2025, Ligand reported total revenue of $268 million (up 60% year-over-year) and royalty revenue of $161 million (up 48% year-over-year), with $124.5 million in GAAP net income compared to a $4 million loss in 2024. Q2 2026 revenue reached $63.7 million (up 34% year-over-year). The company completed a $739 million acquisition of XOMA Royalty in July 2026 and a $700 million 0% convertible senior notes offering in June 2026 to fund inorganic growth. Ligand serves 100+ partner companies spanning multiple therapeutic areas including oncology, rare disease, infectious disease, pulmonology, ophthalmology, and cardiology, with a global operating footprint across the United States and Europe.

Short descriptiontext

Ligand Pharmaceuticals is a publicly traded biopharmaceutical royalty aggregator that provides strategic capital to biopharma companies and manages a diversified portfolio of over 200 royalty assets, with proprietary Captisol® and NITRICIL™ technology platforms and 40+ marketed partnered products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersJupiter, United States
HQ citystring
Jupiter
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical royalties, royalty aggregation, drug development financing, technology licensing, pharmaceutical capital
Industry1 code
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Royalty Financing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Royalty Revenue
TypeLicensing Royalties
Description

Ligand generates revenue through royalties on commercial products developed by partner companies. Key royalty-generating products include Filspari (9% royalty from Travere), Ohtuvayre (3% from Merck), Kyprolis (1.5-3%), Vabysmo (0.50% from Roche), and over 40 other marketed products. Full-year 2025 royalty revenue was $161 million, up 48% year-over-year.

ligand.com
2Captisol Technology Royalties
TypeLicensing Royalties
Description

Revenue from Captisol-enabled drug formulations, with approximately $40 million in royalties in 2025, up 30% year-over-year. Captisol is used in 17 approved therapies.

ligand.com
3Acquisition Royalties (XOMA)
TypeLicensing Royalties
Description

Following the July 2026 XOMA Royalty acquisition, Ligand gained seven commercial products including VABYSMO (Roche), OJEMDA (Servier), and MIPLYFFA (Zevra Therapeutics), plus 14 late-stage development programs and over 100 additional assets.

ligand.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1Royalty rates vary by product and partner agreement
ModelOtherBilling cadenceMonthly
Notes

Key commercial royalty rates: CAPVAXIVE (low-single-digit), FILSPARI (9%), KYPROLIS (1.5-3%), MIPLYFFA (mid-single-digit), OHTUVAYRE (3%), OJEMDA (mid-single-digit), QARZIBA (tiered mid-teens), Teriparatide (25-50% profit share), VABYSMO (0.50%), ZELSUVMI (13%), TZIELD (less than 1%). Pipeline royalties range from low-single-digit to mid-teens.

ligand.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Captisol
Description

Chemically modified cyclodextrin technology platform designed to optimize solubility and stability of drugs. Used by partners including Amgen, Merck, Pfizer, Takeda, and Gilead.

ligand.com
+1 more record
Core offering1 text field

Ligand Pharmaceuticals is a biopharmaceutical royalty aggregator that provides strategic capital to biopharmaceutical companies to finance and advance late-stage clinical development programs. The company manages one of the largest and most diversified portfolios of biopharmaceutical royalties with over 200 commercial, clinical, and preclinical-stage programs, and licenses proprietary technology platforms (Captisol® and NITRICIL™) to pharmaceutical partners. Revenue is generated primarily through royalty streams on approved drugs commercialized by partners such as Merck, Roche, Amgen, and Travere.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Full-year 2025 royalty revenue of $161 million, up 48% year-over-year
+3 more records
Product overview1 text field

Ligand Pharmaceuticals is a leading royalty aggregator that partners with biopharmaceutical companies to finance and advance late-stage clinical development programs. The company operates primarily as an investment platform that acquires and manages royalty assets rather than developing drugs directly. Its core offerings include technology platforms (Captisol® for drug solubility and NITRICIL™ for nitric oxide-based therapeutics available for out-license), and a diversified royalty portfolio spanning more than 200 commercial, clinical, and preclinical-stage assets across multiple therapeutic areas including oncology, rare disease, infectious disease, pulmonology, ophthalmology, and cardiology. Key commercial partnered products include FILSPARI (kidney disease), VABYSMO (ophthalmology), OHTUVAYRE (COPD), KYPROLIS (oncology), and QARZIBA (rare oncology), among approximately 40+ marketed products generating royalties. Investment strategies include Royalty Monetization, M&A, Project Finance, and Platform Technology Acquisitions.

Product and service1 record
1Captisol®
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-07-14
Description

Acquired by Ligand for $739 million ($39 per share). Adds 7 commercial products (VABYSMO, OJEMDA, MIPLYFFA), 14 late-stage development programs, and over 100 additional assets, more than doubling Ligand's portfolio to over 200 royalty assets. Includes CVR tied to Tremfya litigation proceeds.

2APEIRON Biologics AG
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

Acquired by Ligand for $100 million in July 2024. Includes rights to QARZIBA (dinutuximab beta), a treatment for high-risk neuroblastoma approved by EMA in 2017 and marketed in 35 countries. Ligand also invested up to $4 million in APEIRON's spin-off invIOs Holding AG for immuno-oncology development.

ligand.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key royalty partner for OHTUVAYRE (Ensifentrine) for COPD - 3% royalty. Also for CAPVAXIVE and VAXNEUVANCE pneumococcal vaccines - low-single-digit royalties. Q4 2025 sales of Ohtuvayre reached $196 million, up 45% sequentially.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner for FILSPARI (sparsentan) for IgA nephropathy and FSGS - 9% royalty on worldwide net sales. FDA granted full approval for FSGS in April 2026, expanding addressable population to over 100,000 US patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Royalty interest in VABYSMO (faricimab) for wet AMD and diabetic macular edema - 0.50% royalty. Vabysmo is a key royalty driver from XOMA acquisition.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Royalty partner for KYPROLIS (carfilzomib) for relapsed/refractory multiple myeloma - 1.5-3% royalty.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner for QTORIN Rapamycin program - 8-9.8% royalty. Programs in microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Estimated peak sales over $3 billion with ~$285 million potential annual free cash flow to Ligand.

Strategic tierCoreTypeTechnology or Integration
Description

Captisol platform partner using the technology to improve solubility of drug candidates. Also partner for DUAVEE (tiered low-single-digit royalty).

Strategic tierCoreTypeTechnology or Integration
Description

Captisol platform partner which used the technology to improve solubility for Remdesivir (VEKLURY) for COVID-19 treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensing partner for VK2809 (3.5-7.5% royalty for MASH) and VK0214 (undisclosed royalty for X-ALD). Ligand filed notice in May 2026 alleging material breach of 2014 licensing agreement regarding TRβ program.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Royalty financing agreement tied to royalties and milestones from AT220 and AT292 programs. Received $0.5 million milestone in March 2026 with additional $3 million in potential milestones.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

A private healthcare royalty financing firm founded by Ligand CEO Todd Davis. Operates the same royalty-financing and structured-capital model as Ligand and was historically a direct competitor for late-stage biopharma royalty transactions.

TypeEmerging player
Description

Pension-backed investor that has been actively deploying capital into biopharma royalty and structured finance transactions, increasingly overlapping Ligand's late-stage financing and royalty aggregation focus.

TypeDirect peer
Description

Continuation vehicles and successor funds of HealthCare Royalty Partners continue to compete for biopharma royalty deals using the same royalty aggregator thesis pioneered by Todd Davis. They are a direct peer in target assets and deal sourcing.

TypeEmerging player
Description

Healthcare-focused investment firm that participates in biopharma structured financings and royalty deals alongside players like Ligand. Smaller and more focused, but competes for similar late-stage biopharma opportunities.

TypeBroad incumbent
Description

Global healthcare investment firm with dedicated royalty, structured finance, and credit strategies that overlap with Ligand's business model. OrbiMed is broader in mandate (private equity, venture, royalty, credit) but is a meaningful competitor for biopharma royalty financings.

TypeBroad incumbent
Description

Life sciences arm of Blackstone deploying $1B+ biopharma development capital, including royalty and structured financings overlapping Ligand's project finance and royalty monetization strategies. SVP Peter Renehan at Ligand was previously a Principal at Blackstone Life Sciences.

TypeEmerging player
Description

Specialized structured capital provider to late-stage biopharma companies, offering royalty and debt financings that closely mirror Ligand's project finance and royalty monetization strategy.

TypeDirect peer
Description

Canadian-based royalty aggregator that acquires and manages royalty interests in late-stage biopharmaceutical products. Operates a near-identical royalty aggregation model and competes for similar high-quality biopharma royalty streams.

TypeDirect peer
Description

Pre-acquisition, XOMA was a directly comparable royalty aggregator managing royalty interests in commercial and development-stage assets (Vabysmo, Ojemda, Miplyffa, among others). It was Ligand's most direct scaled peer and its 2026 acquisition shows how directly the two competed for similar assets.

TypeDirect peer
Description

The largest publicly traded pharmaceutical royalty buyer (NASDAQ: RPRX), directly comparable in business model: acquires royalty interests in marketed and late-stage biopharma products, then collects long-duration cash flows. Royalty Pharma is the most direct competitor for high-quality biopharma royalty streams.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A14 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment23 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ligand Pharmaceuticals

Biopharmaceutical Royalty Financingligand.com

Ligand Pharmaceuticals is a publicly traded biopharmaceutical royalty aggregator that provides strategic capital to biopharma companies and manages a diversified portfolio of over 200 royalty assets, with proprietary Captisol® and NITRICIL™ technology platforms and 40+ marketed partnered products.

What Ligand Pharmaceuticals does

Ligand Pharmaceuticals is a publicly traded biopharmaceutical royalty aggregator (NASDAQ: LGND) founded in 1987 and headquartered in Jupiter, Florida. The company provides strategic capital to biopharmaceutical companies to finance and advance late-stage clinical development programs, and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with more than 200 commercial, clinical, and preclinical-stage assets following the July 2026 acquisition of XOMA Royalty. Ligand generates revenue primarily through royalties on commercial products developed by partner companies, including key partnered assets such as FILSPARI (9% royalty from Travere for IgA nephropathy and FSGS), OHTUVAYRE (3% from Merck for COPD), VABYSMO (0.50% from Roche), and KYPROLIS (1.5-3% from Amgen).

Ligand operates two proprietary technology platforms. Captisol® is a chemically modified cyclodextrin designed to optimize solubility and stability of drugs, used by partners including Amgen, Merck, Pfizer, Takeda, and Gilead (the latter for Remdesivir for COVID-19). Captisol is incorporated in approximately 17 approved therapies and generated approximately $40 million in royalties in 2025, up 30% year-over-year. NITRICIL™ is a proprietary nitric oxide-based technology platform available for out-license with broad applicability in drug development. The company also conducts supplementary investment activities including royalty financing, project finance, and platform technology acquisitions.

In 2025, Ligand reported total revenue of $268 million (up 60% year-over-year) and royalty revenue of $161 million (up 48% year-over-year), with $124.5 million in GAAP net income compared to a $4 million loss in 2024. Q2 2026 revenue reached $63.7 million (up 34% year-over-year). The company completed a $739 million acquisition of XOMA Royalty in July 2026 and a $700 million 0% convertible senior notes offering in June 2026 to fund inorganic growth. Ligand serves 100+ partner companies spanning multiple therapeutic areas including oncology, rare disease, infectious disease, pulmonology, ophthalmology, and cardiology, with a global operating footprint across the United States and Europe.

Ligand Pharmaceuticals firmographics

Firmographics
Name
Ligand Pharmaceuticals
Legal name
Ligand Pharmaceuticals Incorporated
Website
https://ligand.com
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
101–250 employees
Short description
Ligand Pharmaceuticals is a publicly traded biopharmaceutical royalty aggregator that provides strategic capital to biopharma companies and manages a diversified portfolio of over 200 royalty assets, with proprietary Captisol® and NITRICIL™ technology platforms and 40+ marketed partnered products.
Ownership category
akta.pro rank

Ligand Pharmaceuticals industry classification

Industry
Product category
Biopharmaceutical Royalty Financing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Biopharmaceutical royalties
  • Royalty aggregation
  • Drug development financing
  • Technology licensing
  • Pharmaceutical capital

Where Ligand Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Jupiter
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Ligand Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Royalty Revenue: Ligand generates revenue through royalties on commercial products developed by partner companies. Key royalty-generating products include Filspari (9% royalty from Travere), Ohtuvayre (3% from Merck), Kyprolis (1.5-3%), Vabysmo (0.50% from Roche), and over 40 other marketed products. Full-year 2025 royalty revenue was $161 million, up 48% year-over-year.
  2. Captisol Technology Royalties: Revenue from Captisol-enabled drug formulations, with approximately $40 million in royalties in 2025, up 30% year-over-year. Captisol is used in 17 approved therapies.
  3. Acquisition Royalties (XOMA): Following the July 2026 XOMA Royalty acquisition, Ligand gained seven commercial products including VABYSMO (Roche), OJEMDA (Servier), and MIPLYFFA (Zevra Therapeutics), plus 14 late-stage development programs and over 100 additional assets.

Pricing tiers

ModelBillingPrice
OtherMonthlyRoyalty rates vary by product and partner agreement

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Ligand Pharmaceuticals product offering

Product offering

Core offering

Ligand Pharmaceuticals is a biopharmaceutical royalty aggregator that provides strategic capital to biopharmaceutical companies to finance and advance late-stage clinical development programs. The company manages one of the largest and most diversified portfolios of biopharmaceutical royalties with over 200 commercial, clinical, and preclinical-stage programs, and licenses proprietary technology platforms (Captisol® and NITRICIL™) to pharmaceutical partners. Revenue is generated primarily through royalty streams on approved drugs commercialized by partners such as Merck, Roche, Amgen, and Travere.

Product overview

Ligand Pharmaceuticals is a leading royalty aggregator that partners with biopharmaceutical companies to finance and advance late-stage clinical development programs. The company operates primarily as an investment platform that acquires and manages royalty assets rather than developing drugs directly. Its core offerings include technology platforms (Captisol® for drug solubility and NITRICIL™ for nitric oxide-based therapeutics available for out-license), and a diversified royalty portfolio spanning more than 200 commercial, clinical, and preclinical-stage assets across multiple therapeutic areas including oncology, rare disease, infectious disease, pulmonology, ophthalmology, and cardiology. Key commercial partnered products include FILSPARI (kidney disease), VABYSMO (ophthalmology), OHTUVAYRE (COPD), KYPROLIS (oncology), and QARZIBA (rare oncology), among approximately 40+ marketed products generating royalties. Investment strategies include Royalty Monetization, M&A, Project Finance, and Platform Technology Acquisitions.

Differentiator

Problem solved

Functional benefit

Brands

  • Captisol: Chemically modified cyclodextrin technology platform designed to optimize solubility and stability of drugs. Used by partners including Amgen, Merck, Pfizer, Takeda, and Gilead.
  • NITRICIL

Products and services

  • Captisol®

Quantifiable outcome

  • Full-year 2025 royalty revenue of $161 million, up 48% year-over-year
  • +3 more outcomes

Companies that use Ligand Pharmaceuticals

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Ligand Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Ligand Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • XOMA Royalty CorporationcoreStrategic or Co-development Partner · 14 July 2026Acquired by Ligand for $739 million ($39 per share). Adds 7 commercial products (VABYSMO, OJEMDA, MIPLYFFA), 14 late-stage development programs, and over 100 additional assets, more than doubling Ligand's portfolio to over 200 royalty assets. Includes CVR tied to Tremfya litigation proceeds.
  • APEIRON Biologics AGcoreStrategic or Co-development Partner · 1 July 2024Acquired by Ligand for $100 million in July 2024. Includes rights to QARZIBA (dinutuximab beta), a treatment for high-risk neuroblastoma approved by EMA in 2017 and marketed in 35 countries. Ligand also invested up to $4 million in APEIRON's spin-off invIOs Holding AG for immuno-oncology development.
  • MerckcoreStrategic or Co-development PartnerKey royalty partner for OHTUVAYRE (Ensifentrine) for COPD - 3% royalty. Also for CAPVAXIVE and VAXNEUVANCE pneumococcal vaccines - low-single-digit royalties. Q4 2025 sales of Ohtuvayre reached $196 million, up 45% sequentially.
  • Travere TherapeuticscoreStrategic or Co-development PartnerPartner for FILSPARI (sparsentan) for IgA nephropathy and FSGS - 9% royalty on worldwide net sales. FDA granted full approval for FSGS in April 2026, expanding addressable population to over 100,000 US patients.
  • RochecoreStrategic or Co-development PartnerRoyalty interest in VABYSMO (faricimab) for wet AMD and diabetic macular edema - 0.50% royalty. Vabysmo is a key royalty driver from XOMA acquisition.
  • AmgencoreStrategic or Co-development PartnerRoyalty partner for KYPROLIS (carfilzomib) for relapsed/refractory multiple myeloma - 1.5-3% royalty.
  • Palvella TherapeuticscoreStrategic or Co-development PartnerPartner for QTORIN Rapamycin program - 8-9.8% royalty. Programs in microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Estimated peak sales over $3 billion with ~$285 million potential annual free cash flow to Ligand.
  • PfizercoreTechnology or IntegrationCaptisol platform partner using the technology to improve solubility of drug candidates. Also partner for DUAVEE (tiered low-single-digit royalty).
  • GileadcoreTechnology or IntegrationCaptisol platform partner which used the technology to improve solubility for Remdesivir (VEKLURY) for COVID-19 treatment.
  • Viking TherapeuticscoreStrategic or Co-development PartnerLicensing partner for VK2809 (3.5-7.5% royalty for MASH) and VK0214 (undisclosed royalty for X-ALD). Ligand filed notice in May 2026 alleging material breach of 2014 licensing agreement regarding TRβ program.
  • ArecorminorStrategic or Co-development PartnerRoyalty financing agreement tied to royalties and milestones from AT220 and AT292 programs. Received $0.5 million milestone in March 2026 with additional $3 million in potential milestones.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Ligand Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • HealthCare Royalty Partners: A private healthcare royalty financing firm founded by Ligand CEO Todd Davis. Operates the same royalty-financing and structured-capital model as Ligand and was historically a direct competitor for late-stage biopharma royalty transactions.
  • HealthCare Royalty Partners Fund IV (HCR): Continuation vehicles and successor funds of HealthCare Royalty Partners continue to compete for biopharma royalty deals using the same royalty aggregator thesis pioneered by Todd Davis. They are a direct peer in target assets and deal sourcing.
  • DRI Capital: Canadian-based royalty aggregator that acquires and manages royalty interests in late-stage biopharmaceutical products. Operates a near-identical royalty aggregation model and competes for similar high-quality biopharma royalty streams.
  • XOMA Royalty Corporation: Pre-acquisition, XOMA was a directly comparable royalty aggregator managing royalty interests in commercial and development-stage assets (Vabysmo, Ojemda, Miplyffa, among others). It was Ligand's most direct scaled peer and its 2026 acquisition shows how directly the two competed for similar assets.
  • Royalty Pharma: The largest publicly traded pharmaceutical royalty buyer (NASDAQ: RPRX), directly comparable in business model: acquires royalty interests in marketed and late-stage biopharma products, then collects long-duration cash flows. Royalty Pharma is the most direct competitor for high-quality biopharma royalty streams.

Emerging players

  • OMERS Life Sciences: Pension-backed investor that has been actively deploying capital into biopharma royalty and structured finance transactions, increasingly overlapping Ligand's late-stage financing and royalty aggregation focus.
  • Aisling Capital: Healthcare-focused investment firm that participates in biopharma structured financings and royalty deals alongside players like Ligand. Smaller and more focused, but competes for similar late-stage biopharma opportunities.
  • Pharmakon Advisors: Specialized structured capital provider to late-stage biopharma companies, offering royalty and debt financings that closely mirror Ligand's project finance and royalty monetization strategy.

Broad incumbents

  • OrbiMed: Global healthcare investment firm with dedicated royalty, structured finance, and credit strategies that overlap with Ligand's business model. OrbiMed is broader in mandate (private equity, venture, royalty, credit) but is a meaningful competitor for biopharma royalty financings.
  • Blackstone Life Sciences: Life sciences arm of Blackstone deploying $1B+ biopharma development capital, including royalty and structured financings overlapping Ligand's project finance and royalty monetization strategies. SVP Peter Renehan at Ligand was previously a Principal at Blackstone Life Sciences.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ligand Pharmaceuticals social profiles

Digital presence

Ligand Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ligand Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles15 records

Ligand Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Ligand Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ligand Pharmaceuticals M&A and investment

M&A and investment

M&A14 records

Investments23 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ligand Pharmaceuticals

What does Ligand Pharmaceuticals do?

Ligand Pharmaceuticals is a biopharmaceutical royalty aggregator that provides strategic capital to biopharmaceutical companies to finance and advance late-stage clinical development programs. The company manages one of the largest and most diversified portfolios of biopharmaceutical royalties with over 200 commercial, clinical, and preclinical-stage programs, and licenses proprietary technology platforms (Captisol® and NITRICIL™) to pharmaceutical partners. Revenue is generated primarily through royalty streams on approved drugs commercialized by partners such as Merck, Roche, Amgen, and Travere.

Is Ligand Pharmaceuticals a public or private company?

Ligand Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Ligand Pharmaceuticals founded?

Ligand Pharmaceuticals was founded in 1987. It employs 101 to 250 people.

Where is Ligand Pharmaceuticals based?

Ligand Pharmaceuticals is headquartered in Jupiter, United States, in the North America region.

How does Ligand Pharmaceuticals make money?

Three revenue lines are on record. Royalty Revenue is the primary driver. The others are captisol Technology Royalties and acquisition Royalties (XOMA).

Who are Ligand Pharmaceuticals's main competitors?

Direct peers on record are HealthCare Royalty Partners, HealthCare Royalty Partners Fund IV (HCR), DRI Capital, XOMA Royalty Corporation and Royalty Pharma. Emerging players are OMERS Life Sciences, Aisling Capital and Pharmakon Advisors. Broad incumbents are OrbiMed and Blackstone Life Sciences.

Does Ligand Pharmaceuticals have an API?

No public API is recorded for Ligand Pharmaceuticals.

What industry is Ligand Pharmaceuticals in?

Ligand Pharmaceuticals's product category is Biopharmaceutical Royalty Financing. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldLigand Pharmaceuticals (NASDAQ:LGND) & Applied Therapeutics (NASDAQ:APLT) Head to Head ComparisonLigand Pharmaceuticals and Applied Therapeutics are compared on revenue, earnings, institutional ownership, and analyst ratings. Ligand has higher revenue and earnings, but Applied Therapeutics trades at a lower P/E and has a higher potential upside. Analysts favor Applied Therapeutics due to its higher upside potential.Defense World3,096 Ligand Pharmaceuticals Incorporated $LGND Shares Acquired by Bessemer Group Inc.Bessemer Group increased its Ligand Pharmaceuticals stake by 2.2% in Q3, holding 144,545 shares worth $45.15 million. Ligand reported Q3 EPS of $2.67, beating estimates, but revenue fell 31.8% year-over-year. Analysts have a consensus "Moderate Buy" rating with an average price target of $355.38.TradingViewBarclays maintains Ligand Pharmaceuticals at Overweight, raises price target to $350 from $345Barclays maintained Ligand Pharmaceuticals at Overweight and raised its price target to $350 from $345. The target implies an 11.4% upside from the Nov 10 close of $314.16.Simply Wall StLigand Pharmaceuticals (LGND) Could Be 11% Below Fair Value Following Earnings ShockLigand Pharmaceuticals reported Q3 revenue of $78.75 million and a net loss of $28.49 million, while management reaffirmed full-year sales guidance. Analysts value the stock at $344.25, implying an 11% undervaluation, though the company trades at 119x earnings versus a fair 33.1x. The XOMA Royalty acquisition adds over 120 assets to the royalty portfolio.American Banking and Market NewsLigand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $402.00Citigroup raised its price target on Ligand Pharmaceuticals to $402 from $397, keeping a buy rating. The company reported Q2 EPS of $2.67, beating estimates, but revenue fell 31.8% year-over-year. Analysts have a consensus price target of $354.75.Simply Wall StHow Investors Are Reacting To Ligand Pharmaceuticals Stock After Reaffirmed GuidanceLigand Pharmaceuticals reported Q3 2026 revenue of $78.75 million and a net loss of $28.49 million, while reaffirming full-year 2026 revenue guidance of $270 million to $310 million. Management expects the licensing and royalty portfolio to support the outlook despite the loss. The reaffirmed guidance is the key forward-looking element.Investing.comLigand Pharmaceuticals director sells $90,237 in common stockLigand Pharmaceuticals director Jason Aryeh sold 282 shares on November 4, 2026, for $90,237. The company reported Q3 adjusted EPS of $2.67, beating the $2.33 estimate, and revenue of $78.7 million versus $77 million expected. Stifel raised its price target to $350.Seeking AlphaLigand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy (NASDAQ:LGND)Ligand Pharmaceuticals received a BUY rating, driven by Filspari's 85% year-over-year royalty growth and the accretive XOMA acquisition. XOMA contributed $12.3 million in Q3 royalties, and despite higher SG&A and convertible debt, the company's adjusted EPS guidance and liquidity support a positive outlook.Investing.comLigand Pharmaceuticals director Jason Aryeh sells $676k in sharesLigand Pharmaceuticals director Jason Aryeh sold shares worth $676,158 in late October and early November 2026, at prices near $320. The company reported Q3 revenue of $78.75 million, beating estimates, and adjusted EPS of $2.67. Analyst Stifel raised its price target to $350.TradingViewLigand Pharmaceuticals Director Sold Shares Worth Over $676KLigand Pharmaceuticals director Aryeh Jason sold 2,111 shares on October 30 and November 2, 2026, for approximately $676,158. The October 30 sales ranged from $317.74 to $320.49 per share, and the November 2 sales averaged $320.4261 per share. After the transactions, he directly owned 108,758 shares and indirectly owned 8,000.